A correlational study on MiR-34s and cervical lesions

Objective: The aims of this study were to explore the correlation between MiR-34s and cervical lesions. Materials and Methods: A casecontrol study was conducted. From 2014 to 2015, 120 cases were included and divided into four groups depending on cervical biopsy, including group 0 (cervicitis or normal cervix), group 1 (CINI), group 2 (CINII-III), and group C (cervical cancer); each group included 30 cases. Then the relationship between miRNA-34 family (including miRNA-34a, miRNA-34b, miRNA-34c) and clinical pathological features was analysed based on detection of miRNA-34 by real-time polymerase chain reaction (RT-PCR). Results: The expression level of miRNA-34a in group 0 was 0.19 ± 0.1073, in group 1 it was 0.1507 ±0. 2124, in group 2 it was 0.0766 ± 0.0948 (vs. group 0: p < 0.05), and in group C it was 0.0501 ± 0.0271 (vs. Group 0: p < 0.05). The correlation analysis showed that the expression of miRNA-34a decreased with the aggravating of the cervical lesion (r = -0.4782, p < 0.05), while there was no difference of miRNA-34b (F = 0.5835, p = 0.6282) or miRNA-34c (F = 0.1167, p = 0.9500) in each group. Conclusion: The decrease of miRNA-34a is related with cervical malignant lesion, which may be involved in the pathogenesis by regulating target genes, that may be a new molecular marker for diagnosis and prognosis of cervical cancer.

miRNA-34s; Cervical lesions; Cervical cancer.

[1] Sadalla J.C., Andrade J.M., Genta M.L., Baracat E.C.: “Cervical cancer: what’s new?” Rev. Assoc. Med. Bras. (1992), 2015, 61, 536.

[2] McGuire S.: “World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015”. Adv. Nutr., 2016, 7, 418.

[3] Lorenzi A.T., Fregnani J.H., Possati-Resende J.C., Neto C.S., Villa L.L., Longatto-Filho A.: “Self-collection for high-risk HPV detection in Brazilian women using the careHPV™ test”. Gynecol. Oncol., 2013, 131, 131.

[4] Campos N.G., Sharma M., Clark A., Kim J.J., Resch S.C.: “Resources Required for Cervical Cancer Prevention in Low- and Middle-Income Countries”. PLoS One, 2016, 11, e0164000.

[5] Origoni M., Salvatore S., Perino A., Cucinella G., Candiani M.: “Cervical Intraepithelial Neoplasia (CIN) in pregnancy: the state of the art”. Eur. Rev. Med. Pharmacol. Sci., 2014, 18, 851.

[6] Somashekhar S.P., Ashwin K.R.: “Management of Early Stage Cervical Cancer”. Rev. Recent. Clin. Trials., 2015, 10, 302.

[7] Wang F., Li B., Xie X.: “The roles and clinical significance of microRNAs in cervical cancer”. Histol. Histopathol., 2016, 31, 131.

[8] Ribeiro J., Sousa H.: “MicroRNAs as biomarkers of cervical cancer development: a literature review on miR-125b and miR-34a”. Mol. Biol. Rep., 2014, 41, 1525.

[9] Siemens H., Jackstadt R., Hünten S., Kaller M., Menssen A., Götz U., et al.: “miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions”. Cell Cycle, 2011, 10, 4256.

[10] Agostini M., Knight R.A.: “miR-34: from bench to bedside”. Oncotarget, 2014, 5, 872.

[11] Hermeking H.: “The miR-34 family in cancer and apoptosis”. Cell Death Differ., 2010, 17, 193.

[12] Goh A.M., Coffill C.R., Lane D.P.: “The role of mutant p53 in human cancer”. J. Pathol., 2011, 223, 116.

[13] Bianchi E., Ruberti S., Rontauroli S., Guglielmelli P., Salati S., Rossi C., et al.: “Role of miR-34a-5p in Hematopoietic Progenitor Cells Proliferation and Fate Decision: Novel Insights into the Pathogenesis of Primary Myelofibrosis”. Int. J. Mol. Sci., 2017, 18, E145.

[14] Yang B.H., Bray F.I., Parkin D.M., Sellors J.W., Zhang Z.F.: “Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost”. Int. J. Cancer, 2004, 109, 418.

[15] Fang J., Zhang H., Jin S.: “Epigenetics and cervical cancer: from pathogenesis to therapy”. Tumour Biol., 2014, 35, 5083.

[16] Petry K.U.: “HPV and cervical cancer”. Scand. J. Clin. Lab. Invest. Suppl., 2014, 244, 59.

[17] Goodman A.: “HPV testing as a screen for cervical cancer”. BMJ, 2015, 350, h2372.

[18] Mohr A.M., Mott J.L.: “Overview of microRNA biology”. Semin. Liver Dis., 2015, 35, 3.

[19] Lau N.C., Lim L.P., Weinstein E.G., Bartel D.P.: “An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans”. Science, 2001, 294, 858.

[20] Song R., Walentek P., Sponer N., Klimke A., Lee J.S., Dixon G., et al.: “miR-34/449 miRNAs are required for motile ciliogenesis by repressing cp110”. Nature, 2014, 510, 115.

[21] Wong K.Y., Yu L., Chim C.S.: “DNA methylation of tumor suppressor miRNA genes: a lesson from the miR-34 family”. Epigenomics, 2011, 3, 83.

[22] O’Day E., Lal A.: “MicroRNAs and their target gene networks in breast cancer”. Breast Cancer Res., 2010, 12, 201.

[23] Li Y., Guessous F., Zhang Y., Dipierro C., Kefas B., Johnson E., et al.: “MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes”. Cancer Res., 2009, 69, 7569.

[24] Pang R.T., Leung C.O., Ye T.M., Liu W., Chiu P.C., Lam K.K., et al.: “MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells”. Carcinogenesis, 2010, 31, 1037.

[25] Hagman Z., Haflidadottir B.S., Ansari M., Persson M., Bjartell A., Edsjö A., et al.: “The tumour suppressor miR-34c targets MET in prostate cancer cells”. Br. J. Cancer, 2013, 109, 1271.